A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage

Sanyal, 2019, Past, present and future perspectives in nonalcoholic fatty liver disease, Nat Rev Gastroenterol Hepatol, 16, 377, 10.1038/s41575-019-0144-8 Reimer, 2020, New drugs for NAFLD: lessons from basic models to the clinic, Hepatol Int, 14, 8, 10.1007/s12072-019-10001-4 Bechmann, 2012, The interaction of hepatic lipid and glucose metabolism in liver diseases, J Hepatol, 56, 952, 10.1016/j.jhep.2011.08.025 Zarei, 2021, Revealing the role of peroxisome proliferator-activated receptor beta/delta in nonalcoholic fatty liver disease, Metabolism, 114, 154342, 10.1016/j.metabol.2020.154342 Longo, 2021, Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?, Metabolism, 117, 154708, 10.1016/j.metabol.2021.154708 Wan, 2016, Role of NLRP3 Inflammasome in the progression of NAFLD to NASH, Can J Gastroenterol Hepatol, 2016, 6489012, 10.1155/2016/6489012 Schuster, 2018, Triggering and resolution of inflammation in NASH, Nat Rev Gastroenterol Hepatol, 15, 349, 10.1038/s41575-018-0009-6 Thomas, 2017, A critical role for the NLRP3 inflammasome in NASH, Nat Rev Gastroenterol Hepatol, 14, 197, 10.1038/nrgastro.2017.35 Csak, 2014, Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis, Liver Int, 34, 1402, 10.1111/liv.12537 Dixon, 2013, Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis, PLoS One, 8, 10.1371/journal.pone.0056100 Wree, 2014, NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice, Hepatology (Baltimore, Md), 59, 898, 10.1002/hep.26592 Mridha, 2017, NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice, J Hepatol, 66, 1037, 10.1016/j.jhep.2017.01.022 Szabo, 2012, Inflammasomes in liver diseases, J Hepatol, 57, 642, 10.1016/j.jhep.2012.03.035 Cai, 2017, NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in Kupffer cells induced by palmitic acid, Inflammation, 40, 1875, 10.1007/s10753-017-0628-z Younossi, 2019, Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 394, 2184, 10.1016/S0140-6736(19)33041-7 Zhi-Yu Yang, 2017, Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation, Int J Clin Exp Pathol, 10, 8119 Tolbol, 2018, Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis, World J Gastroenterol, 24, 179, 10.3748/wjg.v24.i2.179 Yang, 2017, Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation, Int J Clin Exp Pathol, 10, 8119 Froh, 2003, Isolation of liver Kupffer cells, Curr Protoc Toxicol Liu, 2020, Activation of SIK1 by phanginin a inhibits hepatic gluconeogenesis by increasing PDE4 activity and suppressing the cAMP signaling pathway, Mol Metab, 41, 101045, 10.1016/j.molmet.2020.101045 Huang, 2012, Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice, Diabetologia, 55, 1469, 10.1007/s00125-011-2366-3 Coll, 2015, A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases, Nat Med, 21, 248, 10.1038/nm.3806 Liang, 2014, Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology, Plos One, 9, 10.1371/journal.pone.0115922 Brunt, 2011, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, Hepatology, 53, 810, 10.1002/hep.24127 Kubota, 2013, A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice, Clin Exp Pharmacol Physiol, 40, 422, 10.1111/1440-1681.12102 Tacke, 2017, Targeting hepatic macrophages to treat liver diseases, J Hepatol, 66, 1300, 10.1016/j.jhep.2017.02.026 Szabo, 2015, Inflammasome activation and function in liver disease, Nat Rev Gastroenterol Hepatol, 12, 387, 10.1038/nrgastro.2015.94 Miura, 2010, Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice, Gastroenterology., 139, 323, 10.1053/j.gastro.2010.03.052 Poynard, 2018, Impact of steatosis and inflammation definitions on the performance of NASH tests, Eur J Gastroenterol Hepatol, 30, 384, 10.1097/MEG.0000000000001033 Zhang, 2019, Macrophage p38 alpha promotes nutritional steatohepatitis through M1 polarization, J Hepatol, 71, 163, 10.1016/j.jhep.2019.03.014 Morrison, 2018, Obeticholic acid modulates serum metabolites and gene signatures characteristic of human NASH and attenuates inflammation and fibrosis progression in Ldlr−/−.Leiden mice, Hepatol Commun, 2, 1513, 10.1002/hep4.1270 Siddiqui, 2020, Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis, J Hepatol, 72, 25, 10.1016/j.jhep.2019.10.006 Swanson, 2019, The NLRP3 inflammasome: molecular activation and regulation to therapeutics, Nat Rev Immunol, 19, 477, 10.1038/s41577-019-0165-0 Coll, 2015, 21, 248 Negrin, 2014, IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis, PLoS One, 9, 10.1371/journal.pone.0107265 Ipsen, 2018, Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease, Cell Mol Life Sci, 75, 3313, 10.1007/s00018-018-2860-6 Van Rooyen, 2011, SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH, J Gastroenterol Hepatol, 26, 789, 10.1111/j.1440-1746.2011.06704.x Hao, 2017, Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis, Cell Metab, 25, 856, 10.1016/j.cmet.2017.03.007 Garcia-Irigoyen, 2017, A novel protective role for FXR against inflammasome activation and endotoxemia, Cell Metab, 25, 763, 10.1016/j.cmet.2017.03.014